Option Therapeutics Inc.

S-1/A amended

Option Therapeutics Inc. is conducting an initial public offering (IPO) of 1,818,182 shares of common stock at an estimated price range of $10.00 to $12.00 per share. The offering follows a separation from its parent company, BioVie Inc., with BioVie retaining at least 60% ownership, making Option a 'controlled company' under NYSE rules. The filing highlights risks related to the separation, reliance on BioVie, and the need for NYSE approval to list the stock.

S-1 filed

Option Therapeutics Inc. is conducting an initial public offering (IPO) of 2,272,727 shares of common stock, with an expected price range of $10.00 to $12.00 per share. The company, a Delaware corporation and wholly owned subsidiary of BioVie Inc., plans to list on NYSE under the symbol 'OPTN'. The offering includes a 45-day option for underwriters to purchase additional shares. The filing reflects a separation from BioVie, with BioVie retaining significant ownership, making Option a 'controlled company' under NYSE rules. The previous DRS/A filing disclosed similar terms but with fewer shares and an earlier date.

DRS/A amended

Option Therapeutics Inc. is conducting an initial public offering (IPO) of 1,818,182 shares of common stock at an estimated price range of $10.00 to $12.00 per share. The company, currently a wholly owned subsidiary of BioVie Inc., plans to list on NYSE American under the symbol OPTN. The filing confirms the separation from BioVie, with BioVie retaining at least 20% ownership, making Option a controlled company exempt from certain NYSE governance rules. The IPO follows a confidential submission and includes updated details on underwriting terms and the company's status as an emerging growth company.

DRS filed

Option Therapeutics Inc. is undergoing its initial public offering (IPO) of common stock, transitioning from a wholly-owned subsidiary of BioVie Inc. to an independent entity. The offering involves issuing up to 100% of its outstanding shares, with BioVie retaining at least 50% ownership, maintaining control under NYSE governance exemptions. The company focuses on developing BIV201, a clinical-stage drug for chronic liver disease, with no prior public market. The IPO price range is unspecified, and listing on NYSE American is conditional on approval.